FJ9

Overview

FJ9 is a NHERF1/PDZ inhibitor with human NHERF1 PDZ1 IC 50 1540 μM, NHERF1 PDZ2 IC 50 160 μM, and Frizzled-7-Dishevelled PDZ complex K i 10 μM. FJ9 binds ligand-binding pockets of NHERF1 PDZ domains to block cognate ligand interactions, disrupts Frizzled-7-Dishevelled interactions, and down-regulates canonical Wnt signaling. FJ9 induces apoptosis in cancer cells with intact β-catenin signaling. FJ9 can be used for the research of non-small cell lung cancer , melanoma.

Application

Products | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Respiratory Cancer | Products > Disease Areas > Melanoma | Products > Disease Areas > Non-Small Cell Lung Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Respiratory Disease | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Na+/H+ Exchanger (NHE) | Products > Signaling Pathways > Wnt | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-182624
• CAS No.: 873841-43-1
• Molecular Formula: C23H27NO3
• Molecular Weight: 365.47
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.
• Availability: In-stock

Source

Original product source